Skip to content

Evaluation of the Right Use of Inhaled Therapeutics

Evaluation of the Right Use of Inhaled Therapeutics Prescribed in Asthma and COPD in Adults

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03395418
Acronym
ARGOS
Enrollment
50
Registered
2018-01-10
Start date
2017-12-01
Completion date
2019-11-01
Last updated
2023-03-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD Asthma

Keywords

COPD, Asthma, Inhaled Therapeutics

Brief summary

Asthma and COPD have a significant impact on public health, affecting about 8 million people in France and generating health care costs of 5.5 billion euros, almost 50% of which are dedicated to long-term treatments are essentially inhaled therapies. The good control of the disease depends on the patient's compliance, but also on the proper use of the devices used for the administration of inhaled drugs under penalty of the degradation of the control of the disease with major medical and medico-economic consequences. Thus, education of these patients in the use of devices must be an integral part of medical care. It comes up against the complexity of the therapeutic arsenal on the one hand and on the other hand with its time-consuming nature: this makes it incompatible with a realization in consultation. The ARGOS process is a telemonitoring project for the support of therapeutic education, consisting in setting up a concrete and real-time relay between prescribers and patients for the education of inhaled therapeutics. Its objective is to provide the answer to what is currently an unmet need in the management of asthma and COPD, with the prospect of a positive impact on the observance of these treatments and by consequently their clinical and economic efficiency.

Interventions

None listed

Sponsors

Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patient followed in Pneumology for asthma or COPD with a prescription for long-term inhaled therapies AND a home health provider (who monitors either home oxygen and / or respiratory equipment) * The patient must have a means of telephone communication in order to be able to be contacted by a provider, an H2AD permanence or a doctor * Patient having given his agreement after having been informed in writing of the purpose and the data collected during this study * Age ≥ 18 years * Beneficiary of a social security scheme

Exclusion criteria

* Refusal of the patient * Patient not understanding French * Absence of home health provider * Absence of means of telephone communication

Design outcomes

Primary

MeasureTime frameDescription
Percentage of exploitable filmsDay 1 to day 7Ratio between the number of exploitable films and the number of films arriving at the telemedicine platform.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026